Literature DB >> 2893929

Topoisomerases in human disease.

R J Epstein1.   

Abstract

Topoisomerases are DNA-modifying enzymes that are becoming increasingly important in clinical practice. These enzymes form a target for antibiotics, autoantibodies, and antitumour drugs, and may also be involved in the pathogenesis of certain genetic disorders. Strategies for clinical manipulation of these nuclear enzyme targets are discussed.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2893929     DOI： 10.1016/s0140-6736(88)91308-6

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  7 in total

1.  Maternal exposure to potential inhibitors of DNA topoisomerase II and infant leukemia (United States): a report from the Children's Cancer Group.

Authors:  J A Ross; J D Potter; G H Reaman; T W Pendergrass; L L Robison
Journal:  Cancer Causes Control       Date:  1996-11       Impact factor: 2.506

Review 2.  Topoisomerases, new targets in cancer chemotherapy.

Authors:  J G Zijlstra; S de Jong; E G de Vries; N H Mulder
Journal:  Med Oncol Tumor Pharmacother       Date:  1990

3.  Autoantibodies to DNA topoisomerase II in cryptogenic fibrosing alveolitis and connective tissue disease.

Authors:  R Meliconi; M Bestagno; C Sturani; C Negri; V Galavotti; C Sala; A Facchini; G Ciarrocchi; G Gasbarrini; G C Astaldi Ricotti
Journal:  Clin Exp Immunol       Date:  1989-05       Impact factor: 4.330

4.  Alteration of topoisomerase II action is a possible molecular mechanism of HL-60 cell differentiation.

Authors:  F Gieseler; F Boege; M Clark
Journal:  Environ Health Perspect       Date:  1990-08       Impact factor: 9.031

5.  DNA topoisomerases from pathogenic fungi: targets for the discovery of antifungal drugs.

Authors:  L L Shen; J Baranowski; J Fostel; D A Montgomery; P A Lartey
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

Review 6.  Antifungal research strategies aiming for new targets.

Authors:  Glorivee Pagán-Mercado; Marielis E Rivera-Ruiz; Frances Segarra-Román; José R Rodríguez-Medina
Journal:  P R Health Sci J       Date:  2009-09       Impact factor: 0.705

7.  Aberrant DNA topoisomerase II activity, radioresistance and inherited susceptibility to cancer.

Authors:  J M Cunningham; G E Francis; M J Holland; K F Pirollo; E H Chang
Journal:  Br J Cancer       Date:  1991-01       Impact factor: 7.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.